DK2041181T3 - Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi - Google Patents

Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi

Info

Publication number
DK2041181T3
DK2041181T3 DK07764590.1T DK07764590T DK2041181T3 DK 2041181 T3 DK2041181 T3 DK 2041181T3 DK 07764590 T DK07764590 T DK 07764590T DK 2041181 T3 DK2041181 T3 DK 2041181T3
Authority
DK
Denmark
Prior art keywords
epcam
cleavage
inhibitor
cancer therapy
protease inhibitors
Prior art date
Application number
DK07764590.1T
Other languages
English (en)
Inventor
Dorothea Maetzel
Markus Muenz
Olivier Gires
Original Assignee
Helmholtz Zentrum Muenchen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06011852A external-priority patent/EP1865001A1/en
Application filed by Helmholtz Zentrum Muenchen filed Critical Helmholtz Zentrum Muenchen
Application granted granted Critical
Publication of DK2041181T3 publication Critical patent/DK2041181T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK07764590.1T 2006-06-08 2007-06-08 Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi DK2041181T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06011852A EP1865001A1 (en) 2006-06-08 2006-06-08 Specific protease inhibitors and their use in cancer therapy
EP07005364 2007-03-15
PCT/EP2007/005077 WO2007141029A1 (en) 2006-06-08 2007-06-08 Specific protease inhibitors and their use in cancer therapy

Publications (1)

Publication Number Publication Date
DK2041181T3 true DK2041181T3 (da) 2011-08-29

Family

ID=38474351

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07764590.1T DK2041181T3 (da) 2006-06-08 2007-06-08 Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi

Country Status (5)

Country Link
US (1) US20100226922A1 (da)
EP (1) EP2041181B1 (da)
AT (1) ATE509956T1 (da)
DK (1) DK2041181T3 (da)
WO (1) WO2007141029A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9110065B2 (en) * 2009-09-21 2015-08-18 Paul Walfish Methods and compositions for the diagnosis and treatment of thyroid cancer
AU2010295172B2 (en) * 2009-09-21 2016-08-04 Ranju Ralhan Methods and compositions for the diagnosis and treatment of thyroid cancer
WO2012158818A2 (en) * 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
EP2541249A1 (en) * 2011-06-28 2013-01-02 Oncotyrol Center for Personalized Cancer Medicine GmbH EpCAM detection
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2058797A1 (en) * 1991-02-01 1992-08-02 Michael John Broadhurst Amino acid derivatives
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
GB2290543B (en) * 1993-03-16 1996-05-22 British Biotech Pharm Hydroxamic acid derivatives as metalloproteinase inhibitors
US5594106A (en) * 1993-08-23 1997-01-14 Immunex Corporation Inhibitors of TNF-α secretion
US5817822A (en) * 1994-06-24 1998-10-06 Novartis Corporation Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic acids
BR9509237A (pt) * 1994-10-05 1997-10-21 Chiroscience Ltd Compostos peptidila e seu uso terapêutico como inibidores de metaloproteases
US5831004A (en) * 1994-10-27 1998-11-03 Affymax Technologies N.V. Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use
DE19540798A1 (de) * 1995-11-02 1997-05-07 Hoechst Ag Alkylxanthinphosphonate und Alkylxanthinphosphinoxide und deren Verwendung als Arzneimittel
RU2164914C2 (ru) * 1995-11-13 2001-04-10 Хехст Акциенгезелльшафт ЦИКЛИЧЕСКИЕ И ГЕТЕРОЦИКЛИЧЕСКИЕ N-ЗАМЕЩЕННЫЕ α-ИМИНОГИДРОКСАМОВЫЕ И КАРБОНОВЫЕ КИСЛОТЫ
US6281352B1 (en) * 1995-11-14 2001-08-28 Dupont Pharmaceuticals Company Macrocyclic compounds as metalloprotease inhibitors
US5665777A (en) * 1995-11-14 1997-09-09 Abbott Laboratories Biphenyl hydroxamate inhibitors of matrix metalloproteinases
GB9523637D0 (en) * 1995-11-18 1996-01-17 British Biotech Pharm Synthesis of carboxylic acid derivatives
US5753653A (en) * 1995-12-08 1998-05-19 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
CA2238306A1 (en) * 1995-12-08 1997-06-12 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation
TW453995B (en) * 1995-12-15 2001-09-11 Novartis Ag Certain alpha-substituted arylsulfonamido acetohydroxamic acids
DE69624081T2 (de) * 1995-12-20 2003-06-12 Agouron Pharmaceuticals, Inc. Matrix-metalloprotease Inhibitoren
GB9607119D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
GB9607120D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
GB9607249D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
ES2194209T3 (es) * 1996-07-22 2003-11-16 Monsanto Co Inhibidores de metaloproteasa de tiol sulfona.
DE69729007T2 (de) * 1996-08-07 2005-04-07 Darwin Discovery Ltd., Slough Hydroxamsäure- und carbonsäure-derivate mit mmp und tnf hemmender wirkung
GB9616643D0 (en) * 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
US5962481A (en) * 1996-10-16 1999-10-05 American Cyanamid Company Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US6228869B1 (en) * 1996-10-16 2001-05-08 American Cyanamid Company Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US6548524B2 (en) * 1996-10-16 2003-04-15 American Cyanamid Company Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US20010051614A1 (en) * 1996-10-16 2001-12-13 Levin Jeremy Ian Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US5929097A (en) * 1996-10-16 1999-07-27 American Cyanamid Company Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US5977408A (en) * 1996-10-16 1999-11-02 American Cyanamid Company Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US5985911A (en) * 1997-01-07 1999-11-16 Abbott Laboratories C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
US5952320A (en) * 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
ZA98376B (en) * 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors
GB9702088D0 (en) * 1997-01-31 1997-03-19 Pharmacia & Upjohn Spa Matrix metalloproteinase inhibitors
US6197791B1 (en) * 1997-02-27 2001-03-06 American Cyanamid Company N-hdroxy-2-(alkyl, aryl, or heteroaryl, sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
US6172057B1 (en) * 1997-02-27 2001-01-09 American Cyanamid Company N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
US6087359A (en) * 1997-03-04 2000-07-11 Getman; Daniel P. Thioaryl sulfonamide hydroxamic acid compounds
US6034136A (en) * 1997-03-20 2000-03-07 Novartis Ag Certain cyclic thio substituted acylaminoacid amide derivatives
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
AU7294098A (en) * 1997-05-09 1998-11-27 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6235787B1 (en) * 1997-06-30 2001-05-22 Hoffmann-La Roche Inc. Hydrazine derivatives
IT1296305B1 (it) * 1997-07-17 1999-06-25 Polifarma Spa Inibitori di metalloproteinasi loro uso terapeutico e procedimento per la produzione del composto di partenza nella loro
ZA988967B (en) * 1997-10-03 2000-04-03 Du Pont Pharm Co Lactam metalloprotease inhibitors.
US6187924B1 (en) * 1997-11-12 2001-02-13 Darwin Discovery, Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
US6063786A (en) * 1997-11-12 2000-05-16 Darwin Discovery, Ltd. Heterocyclic compounds having MMP and TNF inhibitory activity
WO1999024419A1 (en) * 1997-11-12 1999-05-20 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
US20010039287A1 (en) * 1997-11-14 2001-11-08 Thomas E Barta Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US20010014688A1 (en) * 1997-11-14 2001-08-16 Thomas E. Barta Aromatic sulfone hydroxamic acid metalloprotease inhibitor
JP2959765B2 (ja) * 1997-12-12 1999-10-06 日本たばこ産業株式会社 ３−ピペリジル−４−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物
US6071903A (en) * 1998-01-27 2000-06-06 American Cyanamid Company 2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepine-3-hydroxyamic acids
PL200418B1 (pl) * 1998-01-30 2009-01-30 Darwin Discovery Ltd Pochodna N-hydroksyformamidu, zawierający ją środek farmaceutyczny i jej zastosowanie
EP1077974A1 (en) * 1998-05-14 2001-02-28 Du Pont Pharmaceuticals Company Substituted aryl hydroxamic acids as metalloproteinase inhibitors
US6288063B1 (en) * 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
JP3623448B2 (ja) * 1998-08-12 2005-02-23 ファイザー・プロダクツ・インク Ｔａｃｅインヒビター
US6172064B1 (en) * 1998-08-26 2001-01-09 Glaxo Wellcome Inc. Formamides as therapeutic agents
GB9818605D0 (en) * 1998-08-26 1998-10-21 Glaxo Group Ltd Formamide compounds as therepeutic agents
US6277885B1 (en) * 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6762178B2 (en) * 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6340691B1 (en) * 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6326516B1 (en) * 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6200996B1 (en) * 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
AR022423A1 (es) * 1999-01-27 2002-09-04 American Cyanamid Co Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento
US6225311B1 (en) * 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6313123B1 (en) * 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US20010049449A1 (en) * 1999-12-23 2001-12-06 Becker Daniel P. Aromatic sulfonyl alpha-cycloamino hydroxamates and their use as MMP inhibitors
US6458822B2 (en) * 2000-03-13 2002-10-01 Pfizer Inc. 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
JP2003528097A (ja) * 2000-03-17 2003-09-24 ブリストル−マイヤーズ スクイブ ファーマ カンパニー マトリックスメタロプロテアーゼおよびＴＮＦ−α阻害剤としてのβ−アミノ酸誘導体
AU5652001A (en) * 2000-05-15 2001-11-26 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
US6890915B2 (en) * 2001-05-25 2005-05-10 Bristol-Myers Squibb Pharma Company Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
JP2005504042A (ja) * 2001-08-03 2005-02-10 シェーリング　コーポレイション γセクレターゼインヒビターのようなスルホンアミド誘導体
TW200302717A (en) * 2002-02-06 2003-08-16 Schering Corp Novel gamma secretase inhibitors
GB0216382D0 (en) * 2002-07-13 2002-08-21 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
US7122560B2 (en) * 2003-06-18 2006-10-17 Bristol-Myers Squibb Company Lactam derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme
WO2005008250A1 (en) * 2003-07-21 2005-01-27 Angiogenetics Sweden Ab Compounds and methods for promoting angiogenesis by using a gamma-secretase inhibitor or inhibiting the gamma-secretase pathway
WO2005030798A2 (en) * 2003-09-24 2005-04-07 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services TNFαCONVERTING ENZYME INHIBITORY AGENTS AND STIMULATORY AGENTS-
GB0326039D0 (en) * 2003-11-07 2003-12-10 Merck Sharp & Dohme Therapeutic agents
US20050180979A1 (en) * 2004-02-13 2005-08-18 Micromet Ag Anti-EpCAM immunoglobulins
TWI300410B (en) * 2004-04-05 2008-09-01 Schering Corp Novel gamma secretase inhibitors
CA2567343A1 (en) * 2004-05-20 2005-12-01 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
PE20060481A1 (es) * 2004-06-30 2006-06-19 Schering Corp N-arilsulfonilaminas heterociclicas sustituidas como inhibidores de gamma-secretasas
EP1618890B1 (en) * 2004-07-20 2010-10-06 Altropus Gmbh Use of antibodies in a very low dose for the vaccination against cancer
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof

Also Published As

Publication number Publication date
WO2007141029A1 (en) 2007-12-13
ATE509956T1 (de) 2011-06-15
EP2041181B1 (en) 2011-05-18
US20100226922A1 (en) 2010-09-09
EP2041181A1 (en) 2009-04-01

Similar Documents

Publication Publication Date Title
UA94129C2 (ru) Соединения для ингибирования митоза
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
GEP20125537B (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
NO20090628L (no) Pyridizinon derivativater
GEP20146060B (en) Pyridyl inhibitors of hedgehog signalling
JO2998B1 (ar) مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
MY183014A (en) Compounds for enzyme inhibition
MX2009013565A (es) Derivados de azapeptidos.
DK1846424T3 (da) Proteasom-inhibitorer og fremgangsmåder til anvendelse deraf
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
UA93425C2 (ru) Производные гидантоина, которые применяются kak mmp ингибиторы
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
EA200601391A1 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
CL2008002185A1 (es) Compuestos derivados de pirimidina, inhibidores de fosfatidilinositol-3-cinasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades resapiratorias, alergias, inflamacion, cancer, entre otras enfermedades.
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
DK2041181T3 (da) Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi
MA32183B1 (fr) Pyrimidylcyclopentanes hydroxylés utilisés comme inhibiteurs de protéine kinase akt
NO20091495L (no) Pyrazolopyrimidinderivat
EA200970164A1 (ru) Ингибиторы каспазы на основе пиридазинонового каркаса
IL191670A0 (en) Compounds for the inhibition of apoptosis
WO2009148600A8 (en) Deuterated lysine-based compounds
TW200639155A (en) Thiazolidinones, their production and use as pharmaceutical agents
ATE496899T1 (de) Tetrahydro- und dihydrochinazolinone